Lack of immunoediting in murine pancreatic cancer reversed with neoantigen.

Evans RA, Diamond MS, Rech AJ, Chao T, Richardson MW, Lin JH, Bajor DL, Byrne KT, Stanger BZ, Riley JL, Markosyan N, Winograd R, Vonderheide RH; JCI Insight. 2016-09-08.

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.

Winograd, R.,Byrne, K. T.,Evans, R. A.,Odorizzi, P. M.,Meyer, A. R.,Bajor, D. L.,Clendenin, C.,Stanger, B. Z.,Furth, E. E.,Wherry, E. J.,Vonderheide, R. H.; Cancer Immunol Res. 2015 Feb 14.

Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.

Bajor, D. L.,Xu, X.,Torigian, D. A.,Mick, R.,Garcia, L. R.,Richman, L. P.,Desmarais, C.,Nathanson, K. L.,Schuchter, L. M.,Kalos, M.,Vonderheide, R. H.; Cancer Immunol Res. 2014 Sep 26.